Population pharmacokinetics of faropenem in healthy human volunteers and patients

Hideki Hirooka, Masahiro Sou, Koji Miyata, Kohya Shiba, Yusuke Tanigawara

研究成果: Article

抄録

Faropenem (FRPM) is an oral penem antibacterial medicine with a high stability to beta-lactamase which has a broad antibacterial spectrum and a strong antibacterial activity to gram positive bacteria, and gram negative bacteria, except for Pseudomonas aeruginosa and anaerobic bacteria. The sale of faropenem was started in 1997. Based on the plasma faropenem concentration vs. time data obtained from clinical trials using healthy adult volunteers and patients, and a post-marketing clinical study using advanced age patients, the population pharmacokinetic analysis of a total of 20 studies was performed. The concentration data of 1,065 points from 218 patients whose creatinine clearances were measured (85 points/12 patients) or estimated (980 points/206 patients) from plasma concentration levels was used for the analysis. A one-compartment model with first-order absorption was used as a pharmacokinetic model where the absorption lag-time was assumed. Among the population pharmacokinetic parameters, the apparent total body clearance (CL), apparent distribution volume (V), first-order absorption rate constant (ka) and absorption lag-time (tlag) showed great inter-subject variation. In the final model, creatinine clearance (CLcr) was chosen as the most influential covariate against CL and CL was well correlated with CLcr when CLcr was less than 80 mL/min. The inter-subject variability in CL was explained by considering CLcr as a cofactor. The apparent distribution volume increased in the geriatric patients. Both ka and tlag were dependent on meals in all patients. Based on these results, the population pharmacokinetic model of faropenem was made by taking these covariates into consideration. From the results of population pharmacokinetics analysis, the prolongation of the elimination half-life (t1/2) of faropenem was suggested in the patients with decreased kidney function as previously reported.

元の言語English
ページ(範囲)197-207
ページ数11
ジャーナルJapanese Journal of Clinical Pharmacology and Therapeutics
36
発行部数4
出版物ステータスPublished - 2005 7

Fingerprint

Healthy Volunteers
Pharmacokinetics
Population
meropenem
Creatinine
Anaerobic Bacteria
fropenem
Gram-Positive Bacteria
beta-Lactamases
Marketing
Gram-Negative Bacteria
Geriatrics
Pseudomonas aeruginosa
Half-Life
Meals
Clinical Trials
Kidney

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

これを引用

Population pharmacokinetics of faropenem in healthy human volunteers and patients. / Hirooka, Hideki; Sou, Masahiro; Miyata, Koji; Shiba, Kohya; Tanigawara, Yusuke.

:: Japanese Journal of Clinical Pharmacology and Therapeutics, 巻 36, 番号 4, 07.2005, p. 197-207.

研究成果: Article

Hirooka, Hideki ; Sou, Masahiro ; Miyata, Koji ; Shiba, Kohya ; Tanigawara, Yusuke. / Population pharmacokinetics of faropenem in healthy human volunteers and patients. :: Japanese Journal of Clinical Pharmacology and Therapeutics. 2005 ; 巻 36, 番号 4. pp. 197-207.
@article{832a542f880149a69c017bc4e0e76d0f,
title = "Population pharmacokinetics of faropenem in healthy human volunteers and patients",
abstract = "Faropenem (FRPM) is an oral penem antibacterial medicine with a high stability to beta-lactamase which has a broad antibacterial spectrum and a strong antibacterial activity to gram positive bacteria, and gram negative bacteria, except for Pseudomonas aeruginosa and anaerobic bacteria. The sale of faropenem was started in 1997. Based on the plasma faropenem concentration vs. time data obtained from clinical trials using healthy adult volunteers and patients, and a post-marketing clinical study using advanced age patients, the population pharmacokinetic analysis of a total of 20 studies was performed. The concentration data of 1,065 points from 218 patients whose creatinine clearances were measured (85 points/12 patients) or estimated (980 points/206 patients) from plasma concentration levels was used for the analysis. A one-compartment model with first-order absorption was used as a pharmacokinetic model where the absorption lag-time was assumed. Among the population pharmacokinetic parameters, the apparent total body clearance (CL), apparent distribution volume (V), first-order absorption rate constant (ka) and absorption lag-time (tlag) showed great inter-subject variation. In the final model, creatinine clearance (CLcr) was chosen as the most influential covariate against CL and CL was well correlated with CLcr when CLcr was less than 80 mL/min. The inter-subject variability in CL was explained by considering CLcr as a cofactor. The apparent distribution volume increased in the geriatric patients. Both ka and tlag were dependent on meals in all patients. Based on these results, the population pharmacokinetic model of faropenem was made by taking these covariates into consideration. From the results of population pharmacokinetics analysis, the prolongation of the elimination half-life (t1/2) of faropenem was suggested in the patients with decreased kidney function as previously reported.",
keywords = "FRPM, Population pharmacokinetics",
author = "Hideki Hirooka and Masahiro Sou and Koji Miyata and Kohya Shiba and Yusuke Tanigawara",
year = "2005",
month = "7",
language = "English",
volume = "36",
pages = "197--207",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "4",

}

TY - JOUR

T1 - Population pharmacokinetics of faropenem in healthy human volunteers and patients

AU - Hirooka, Hideki

AU - Sou, Masahiro

AU - Miyata, Koji

AU - Shiba, Kohya

AU - Tanigawara, Yusuke

PY - 2005/7

Y1 - 2005/7

N2 - Faropenem (FRPM) is an oral penem antibacterial medicine with a high stability to beta-lactamase which has a broad antibacterial spectrum and a strong antibacterial activity to gram positive bacteria, and gram negative bacteria, except for Pseudomonas aeruginosa and anaerobic bacteria. The sale of faropenem was started in 1997. Based on the plasma faropenem concentration vs. time data obtained from clinical trials using healthy adult volunteers and patients, and a post-marketing clinical study using advanced age patients, the population pharmacokinetic analysis of a total of 20 studies was performed. The concentration data of 1,065 points from 218 patients whose creatinine clearances were measured (85 points/12 patients) or estimated (980 points/206 patients) from plasma concentration levels was used for the analysis. A one-compartment model with first-order absorption was used as a pharmacokinetic model where the absorption lag-time was assumed. Among the population pharmacokinetic parameters, the apparent total body clearance (CL), apparent distribution volume (V), first-order absorption rate constant (ka) and absorption lag-time (tlag) showed great inter-subject variation. In the final model, creatinine clearance (CLcr) was chosen as the most influential covariate against CL and CL was well correlated with CLcr when CLcr was less than 80 mL/min. The inter-subject variability in CL was explained by considering CLcr as a cofactor. The apparent distribution volume increased in the geriatric patients. Both ka and tlag were dependent on meals in all patients. Based on these results, the population pharmacokinetic model of faropenem was made by taking these covariates into consideration. From the results of population pharmacokinetics analysis, the prolongation of the elimination half-life (t1/2) of faropenem was suggested in the patients with decreased kidney function as previously reported.

AB - Faropenem (FRPM) is an oral penem antibacterial medicine with a high stability to beta-lactamase which has a broad antibacterial spectrum and a strong antibacterial activity to gram positive bacteria, and gram negative bacteria, except for Pseudomonas aeruginosa and anaerobic bacteria. The sale of faropenem was started in 1997. Based on the plasma faropenem concentration vs. time data obtained from clinical trials using healthy adult volunteers and patients, and a post-marketing clinical study using advanced age patients, the population pharmacokinetic analysis of a total of 20 studies was performed. The concentration data of 1,065 points from 218 patients whose creatinine clearances were measured (85 points/12 patients) or estimated (980 points/206 patients) from plasma concentration levels was used for the analysis. A one-compartment model with first-order absorption was used as a pharmacokinetic model where the absorption lag-time was assumed. Among the population pharmacokinetic parameters, the apparent total body clearance (CL), apparent distribution volume (V), first-order absorption rate constant (ka) and absorption lag-time (tlag) showed great inter-subject variation. In the final model, creatinine clearance (CLcr) was chosen as the most influential covariate against CL and CL was well correlated with CLcr when CLcr was less than 80 mL/min. The inter-subject variability in CL was explained by considering CLcr as a cofactor. The apparent distribution volume increased in the geriatric patients. Both ka and tlag were dependent on meals in all patients. Based on these results, the population pharmacokinetic model of faropenem was made by taking these covariates into consideration. From the results of population pharmacokinetics analysis, the prolongation of the elimination half-life (t1/2) of faropenem was suggested in the patients with decreased kidney function as previously reported.

KW - FRPM

KW - Population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=24644470616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644470616&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:24644470616

VL - 36

SP - 197

EP - 207

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 4

ER -